BioCentury
ARTICLE | Clinical News

ATX-MS-1467: Phase I started

May 24, 2010 7:00 AM UTC

Apitope began a U.K. Phase I trial in 40 patients to evaluate intra-dermal or subcutaneous ATX-MS-1467 given every 2 weeks for 16 weeks, followed by a 24-week follow-up period. Apitope is developing A...